Quality Assessment of Systematic Reviews of Health Economic Evaluations: Pitfalls with the Application of the PRISMA Statement. Comment on Quang et al. (Sys Rev Pharm. 2017;8(1):52-61)

Systematic Reviews in Pharmacy,2018,9,1,83-84.
Published:December 2017
Type:Letter to the Editor

Quality Assessment of Systematic Reviews of Health Economic Evaluations: Pitfalls with the Application of the PRISMA Statement. Comment on Quang et al. (Sys Rev Pharm. 2017;8(1):52-61)

Miriam Luhnen1*, Siw Waffenschmidt1, Anja Schwalm1, Andreas Gerber-Grote2, Gloria Hanke3

1Institute for Quality and Efficiency in Health Care (IQWiG), Department Health Care and Health Economics, Im Mediapark 8, 50670 Cologne, GERMANY.

2Zurich University of Applied Sciences, School of Health Professions, Winterthur, SWITZERLAND.

3Department of Palliative Medicine, University Hospital of Cologne, Cologne, GERMANY.

Abstract:

In a recently published article, Quang et al. evaluate the quality of systematic reviews of health economic evaluations of interventions for hepatitis.1 As the authors of one of the systematic reviews included in the assessment,2 we would like to discuss the methods which were applied and which, in our opinion, seem to be inappropriate.